Stock Update (NASDAQ:RPTP): Raptor Pharmaceutical Corp. Announces Management Changes

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) announced the appointment of Ashley Gould, J.D. as its Senior Vice President, General Counsel and Corporate Governance. In addition, Ted Daley, Chief Business Officer, will be leaving the company at the end of September to pursue other interests.

“I am delighted to welcome Ashley to Raptor’s executive team,” said Julie Anne Smith, President and CEO of Raptor Pharmaceutical. “She has highly relevant expertise in biopharma spanning regulatory, quality assurance, governmental, and legal in addition to other functions. As Raptor continues to grow, I am confident she will prove an excellent strategic addition and I look forward to her counsel. Separately, I would like to thank Ted for all of the contributions he has made to Raptor’s success over the years. His involvement across all functions has been invaluable as we’ve grown into a commercial, global organization. On behalf of the Board and other members of the executive team, we wish him well in his future endeavors.”

Most recently Ms. Gould served as Senior Vice President, Governmental Affairs and Chief Legal and Compliance Officer for Hyperion Therapeutics. Before that, she held a number of positions of increasing responsibility at 23andMe, culminating in her appointment as Vice President, Corporate Development and Chief Legal Officer. Previously she was Vice President, Legal Affairs at CoTherix, where she worked on the company’s acquisition by Actelion, and an associate at the law firms of O’Melveny & Myers and Wilson Sonsini Goodrich & Rosati. Ms. Gould received a B.S. in Political Economy of Natural Resources from University of California, Berkeley and a J.D. from the University of San Francisco School of Law. (Original Source)

Shares of Raptor Pharmaceutical Corp. closed yesterday at $14.76. RPTP has a 1-year high of $16.28 and a 1-year low of $7.85. The stock’s 50-day moving average is $14.31 and its 200-day moving average is $11.41.

On the ratings front, Oppenheimer analyst Christopher Marai downgraded RPTP to Sell, with a price target of $8, in a report issued on July 6. The current price target reflects a potential downside of -45.8% from last closing price. According to, Marai has a total average return of 48.3%, a 74.5% success rate, and is ranked #7 out of 3708 analysts.

Raptor Pharmaceutical Corp is abiopharmaceuticalcompany. It is engaged indeveloping and commercializing transformative treatments for people affected by rare and debilitating diseases.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts